Literature DB >> 26629283

Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK -Positive Non-Small-Cell Lung Cancer.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2015        PMID： 26629283      PMCID： PMC4665050     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  6 in total

1.  American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Authors:  Christopher G Azzoli; Giuseppe Giaccone; Sarah Temin
Journal:  J Oncol Pract       Date:  2010-01       Impact factor: 3.840

2.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

3.  A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada.

Authors:  V Hirsh; B Melosky; G Goss; D Morris; W Morzycki
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

4.  KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:  Erminia Massarelli; Marileila Varella-Garcia; Ximing Tang; Ana C Xavier; Natalie C Ozburn; Diane D Liu; Benjamin N Bekele; Roy S Herbst; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

5.  Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?

Authors:  Victoria M Villaflor; Ravi Salgia
Journal:  J Carcinog       Date:  2013-03-18

Review 6.  Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.

Authors:  Eiji Iwama; Isamu Okamoto; Taishi Harada; Koichi Takayama; Yoichi Nakanishi
Journal:  Onco Targets Ther       Date:  2014-03-05       Impact factor: 4.147
  6 in total
  5 in total

Review 1.  Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.

Authors:  M Drizou; E A Kotteas; N Syrigos
Journal:  Clin Transl Oncol       Date:  2017-01-04       Impact factor: 3.405

2.  Recurrent hyperglycemic hyperosmolar state after re-administration of dose-reduced ceritinib, an anaplastic lymphoma kinase inhibitor.

Authors:  Yuka Miyoshi; Osamu Ogawa; Ai Nishida; Masahiro Masuzawa
Journal:  Diabetol Int       Date:  2020-06-02

3.  Dynamic Meta-data Network Sparse PCA for Cancer Subtype Biomarker Screening.

Authors:  Rui Miao; Xin Dong; Xiao-Ying Liu; Sio-Long Lo; Xin-Yue Mei; Qi Dang; Jie Cai; Shao Li; Kuo Yang; Sheng-Li Xie; Yong Liang
Journal:  Front Genet       Date:  2022-05-09       Impact factor: 4.772

4.  Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis.

Authors:  Anand A Dalal; Annie Guerin; Alex Mutebi; Kenneth W Culver
Journal:  J Drug Assess       Date:  2018-03-12

5.  Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.

Authors:  Nai-Jung Chiang; Chiun Hsu; Jen-Shi Chen; Hsiao-Hui Tsou; Ying-Ying Shen; Yee Chao; Ming-Huang Chen; Ta-Sen Yeh; Yan-Shen Shan; Shiu-Feng Huang; Li-Tzong Chen
Journal:  Sci Rep       Date:  2016-05-03       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.